title: Will symptom-based therapy be effective for treating asthma in children?
abstract: Traditionally, symptoms are important patient-oriented outcomes in asthma treatment, and assessment of symptoms is an essential component of assessing asthma control. However, variable airways obstruction, airways hyperresponsiveness and chronic inflammation are key components of the asthma syndrome, and correlations among these hallmarks and symptoms are weak or even absent. Therefore, it might be questioned if symptom-based therapy is effective for treating asthma in (all) children. To date, there is no firm indication that monitoring asthma based on repetitive lung function measurement or markers of airway inflammation is superior to monitoring based on symptoms only. In the majority of patients, symptom-based asthma management may well be sufficient, and in preschool children, symptoms are presently the only feasible outcome. Nevertheless, there is some evidence that selected groups might benefit from an approach that takes into account individual phenotypic characteristics. In patients with poor perception, those with a discordant phenotype and those with persistent severe asthma, considering lung function, airways hyperresponsiveness and inflammatory markers in treatment decisions might improve outcomes.
authors.affiliation: Department of Paediatrics, Juliana Children's Hospital, The Hague, The Netherlands, m.nuijsink@hagaziekenhuis.nl.
authors.forename: Marianne
authors.initials: M
authors.lastname: Nuijsink
authors.forename: Johan C
authors.initials: JC
authors.lastname: De Jongste
authors.forename: Mariëlle W
authors.initials: MW
authors.lastname: Pijnenburg
mesh_terms: D000402:Airway Obstruction / Q000188:drug therapy / Q000503:physiopathology; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers; D002648:Child; D006801:Humans; D008168:Lung / Q000503:physiopathology; D010641:Phenotype
chemical_list: D018927:Anti-Asthmatic Agents; D015415:Biomarkers